Rheumatology Medical News about rheumatoid arthritis;spondyloarthropathy;tumor necrosis factor alpha inhibition;bone density

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy
Seminars in Arthritis and Rheumatism, 06/30/09

Barnabe C et al. - Anti-TNFα therapies are reported to have beneficial effects on bone density and bone turnover markers. However, retrieved studies in this review were heterogeneous with regards to patients studied, underlying risks for osteoporosis, and supplemental therapy, which may limit the findings of the true effect of anti-TNFα therapy on bone.

Methods

Review of current literature reporting on:
- Effect of anti-TNFα on bone density as measured by DEXA at the lumbar spine and hip
- Effect on markers of bone turnover and resorption, in pts using anti-TNFα for rheumatic disease indications
PubMed search, as well as manual search of related articles and references of articles retrieved
Studies pertaining to the effect of anti-TNFα therapy on BMD and bone turnover markers were included

Results

In RA, 4 studies (238 pts) showed a stabilization or increase of BMD at the spine or hip with only 1 negative study in 48 pts
In spondyloarthopathies, 3 studies (75 pts) all demonstrated an increase in BMD at the lumbar spine and at the hip
Changes in markers of bone formation and bone resorption were heterogeneous but in general represented a modest increase in formation and decline in resorption

<< Previous
The role of capillaroscopy in differentiation of primary and...

Next >>
Augmentation index and large-artery remodeling in patients with...

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09 Relevance Score: 71%

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09 Relevance Score: 70%

Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09 Relevance Score: 70%

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09 Relevance Score: 69%

Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09 Relevance Score: 69%